MET and glioblastoma: First, we validated that Crizotinib acts on-target by confirming in whole cell protein lysates of NCH644 GBM stem-like cells and U87 cells that Crizotinib elicits a reduction in phosphorylation of c-MET (Supplementary Figure 1C), confirming that this compound is active in our model systems.